Literature DB >> 14499321

Tardive dyskinesia in Chinese inpatients with chronic schizophrenia.

Siu-Kau Leung1, Gabor S Ungvari, Fung-Shing Ng, Hung-Kin Cheung, Tony Leung.   

Abstract

The objective of the study was to determine the point prevalence of tardive dyskinesia (TD) in Chinese inpatients with chronic schizophrenia and its association with sociodemographic, clinical and treatment variables and other movement disorders. A cross-sectional assessment of a randomly selected cohort of inpatients (n=225; mean age=42+/-7 years) with DSM-IV schizophrenia was employed using standard rating instruments for TD and other drug-induced movement disorders, in addition to catatonia, and psychotic, negative, depressive and obsessive-compulsive symptoms. Using Schooler and Kane's criteria, 15 subjects (6.7%) had TD. Patients with TD were significantly older and significantly fewer of them were taking antiparkinsonian medication than subjects without TD. There was no significant difference between the TD and non-TD groups with respect to other demographic, clinical and treatment variables including sex, age of onset, length of contact with psychiatric services, current antipsychotic dosage, negative symptoms, catatonia and parkinsonism. The results confirmed the low prevalence of TD in patients with chronic schizophrenia compared to those found in Caucasian patients. The study has also replicated the association of TD in Chinese schizophrenia patients with older age but failed to demonstrate any association between TD and other demographic or clinical characteristics including catatonia.

Entities:  

Mesh:

Year:  2003        PMID: 14499321     DOI: 10.1016/S0278-5846(03)00171-4

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  1 in total

1.  Rating catatonia in patients with chronic schizophrenia: Rasch analysis of the Bush-Francis Catatonia Rating Scale.

Authors:  Eric Wong; Gabor S Ungvari; Siu-Kau Leung; Wai-Kwong Tang
Journal:  Int J Methods Psychiatr Res       Date:  2007       Impact factor: 4.035

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.